Nanobiotix Files Routine 6-K Disclosure
Ticker: NBTX · Form: 6-K · Filed: Jan 29, 2025 · CIK: 1760854
Sentiment: neutral
Topics: disclosure, sec-filing, routine-report
TL;DR
Nanobiotix filed a 6-K, just a routine check-in, no new info.
AI Summary
Nanobiotix S.A. filed a Form 6-K on January 29, 2025, to report its status as a foreign private issuer. The company, based in Paris, France, is required to file annual reports under Form 20-F. This filing does not contain specific financial figures or operational updates but serves as a routine disclosure.
Why It Matters
This filing is a standard procedural document for foreign private issuers, indicating ongoing compliance with SEC reporting requirements. It does not provide new business or financial information.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new material information that would impact the company's risk profile.
Key Players & Entities
- Nanobiotix S.A. (company) — Filer of the Form 6-K
- Paris, France (location) — Company's principal executive office location
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of January 2025.
Does Nanobiotix S.A. file annual reports under Form 20-F or 40-F?
Nanobiotix S.A. indicates it files annual reports under cover of Form 20-F.
What is the principal executive office address of Nanobiotix S.A.?
The principal executive office is located at 60 Rue de Wattignies, 75012 Paris, France.
What is the Commission File Number for Nanobiotix S.A.?
The Commission File Number is 001-39777.
Is this filing submitting the Form 6-K in paper as permitted by Regulation S-T?
The filing includes check boxes for submission in paper under Rule 101(b)(1) and Rule 101(b)(7) of Regulation S-T, but does not explicitly state that this specific filing is being submitted in paper under those provisions.
Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2025-01-29 16:15:04
Filing Documents
- f6k_012925.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 5KB
- 0001171843-25-000507.txt ( ) — 11KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: January 29, 2025 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer